Vieira Roberto Wandenkolk 的 Form 4 申報

Corcept Therapeutics Inc（CORT），2026/9/3 申報

申報編號: 0001193125-26-382456
申報時間: 2026/9/3 21:02 ET
交易日: 2026/9/1-9/2
申報延遲: 2 天
10b5-1 計畫: 有勾選

SEC EDGAR 原文（在新分頁開啟）

這份申報列了 11 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $646.1 萬。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人	與公司的關係
Vieira Roberto WandenkolkCIK 0002150104	高階主管（President, Oncology）

非衍生性證券（表 I）

普通股等股票的取得與處分，每一列是申報上的一筆。

非衍生性證券的交易
交易日	證券	交易	股數	價格	金額	交易後持股	持有方式
2026/9/1	Common Stock	A公司授予取得	+138	$113.38^F2	+$15,646.44	4,206	直接
2026/9/1	Common Stock	A公司授予取得	+138	$0.00	$0	4,344	直接
2026/9/2	Common Stock	F扣股繳稅處分	−102	$113.38^F6	−$11,564.76	4,242	直接
2026/9/2	Common Stock	M行使選擇權取得	+58,333	$21.63	+$1,261,742.79	62,575	直接
2026/9/2	Common Stock	S賣出處分	−23,600	$109.35^F9	−$2,580,674.16	38,975	直接
2026/9/2	Common Stock	S賣出處分	−23,770	$110.70^F10	−$2,631,348.51	15,205	直接
2026/9/2	Common Stock	S賣出處分	−1,537	$111.37^F11	−$171,180.76	13,668	直接
2026/9/2	Common Stock	S賣出處分	−974	$112.40^F12	−$109,474.29	12,694	直接
2026/9/2	Common Stock	S賣出處分	−1,606	$113.72^F13	−$182,632.23	11,088	直接
2026/9/2	Common Stock	S賣出處分	−5,621	$114.58^F14	−$644,042.38	5,467	直接
2026/9/2	Common Stock	S賣出處分	−1,225	$115.44^F15	−$141,413.39	4,242	直接

衍生性證券（表 II）

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日	證券	交易	標的股數	單價	金額	交易後持有	持有方式	旗標
2026/9/2	Common Stock	M行使選擇權處分	−58,333	$0.00	$0	141,667	直接

附註與備註

本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。

In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

表 I 有 1 筆交易的價格引用這則附註。

The closing price on September 1, 2026 was used to calculate the withholding obligation.

表 I 有 1 筆交易的價格引用這則附註。

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F10

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F11

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F12

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F13

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F14

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

F15

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

表 I 有 1 筆交易的價格引用這則附註。

備註

The power of attorney under which this form was signed is on file with the Commission.

看 SEC EDGAR 上的完整原文（在新分頁開啟）